UpFront Diagnostics has secured CE mark approval for LVOne, a rapid blood test designed to identify large-vessel-occlusion stroke in pre-hospital settings.

Proteomics International has begun the controlled commercial rollout of its PromarkerD and PromarkerEso blood tests in Western Australia and the Northern Territory through its exclusive pathology distribution agreement with Healius.

Bluejay Diagnostics and Lovell Government Services have formed a distribution and co-marketing partnership to prepare Bluejay's Symphony diagnostic platform for access to US federal healthcare markets following regulatory authorisation.

Renalytix has signed a multi-year agreement with Quest Diagnostics to expand US access to its kidneyintelX.dkd blood test for patients with type 2 diabetes and chronic kidney disease.

The clearance extends FDA-authorised blood-based assessment of Alzheimer’s-associated amyloid pathology to younger symptomatic adults, providing clinicians with a less invasive alternative to PET imaging and cerebrospinal fluid testing.

The company has expanded its US clinical validation study to support a future FDA submission for its adult NGAL kidney injury test while continuing to grow adoption of the biomarker in clinical practice.

The collaborative initiative aims to generate evidence on the consistency of next-generation sequencing (NGS) testing across routine clinical laboratories, supporting future improvements in precision oncology diagnostics.

The authorisation introduces the first autonomous robotic system designed to perform blood collection under phlebotomist supervision, supporting outpatient services facing workforce pressures.

The Canadian authorisation moves Light AI’s AI-enabled throat-image analysis platform from investigational development into its first regulated market, providing healthcare professionals with a software-based tool to support assessment of suspected Group A Streptococcus infection.

The collaboration will connect ChemoMetec’s XcytoMatic 30 cell counter with Roche’s Cedex Bio Analyzer and establish a joint go-to-market strategy for the combined bioprocess monitoring solution.

EndoSure and Ziwig Endotest will be introduced as complementary diagnostic options, aiming to reduce delays in diagnosis for millions of women affected by endometriosis.